Retinoblastoma (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinoblastoma – Drugs In Development, 2021, provides an overview of the Retinoblastoma (Oncology) pipeline landscape.Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinoblastoma – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Retinoblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Retinoblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 3 and 10 respectively.

Retinoblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Retinoblastoma (Oncology).

– The pipeline guide reviews pipeline therapeutics for Retinoblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Retinoblastoma (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Retinoblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Retinoblastoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Retinoblastoma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Retinoblastoma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Aileron Therapeutics Inc

APEIRON Biologics AG

Ascentage Pharma Group International

Canget BioTekpharma LLC

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Innovation Pharmaceuticals Inc

Oxular Ltd

PepVax Inc

Seneca Therapeutics Inc

Spectocular LLC

Targeted Therapy Technologies LLC

VCN Biosciences SL

Y-mAbs Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinoblastoma - Overview

Retinoblastoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Retinoblastoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinoblastoma - Companies Involved in Therapeutics Development

Aileron Therapeutics Inc

APEIRON Biologics AG

Ascentage Pharma Group International

Canget BioTekpharma LLC

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Innovation Pharmaceuticals Inc

Oxular Ltd

PepVax Inc

Seneca Therapeutics Inc

Spectocular LLC

Targeted Therapy Technologies LLC

VCN Biosciences SL

Y-mAbs Therapeutics Inc

Retinoblastoma - Drug Profiles

ALRN-6924 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APG-115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bi-specific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

conbercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit MDM2 for Retinoblastoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FL-761 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FL-7729 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FL-7N1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kevetrin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lorukafusp alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OXU-003 SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit MDM2 for Unspecified Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SVV-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

topotecan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCN-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinoblastoma - Dormant Projects

Retinoblastoma - Product Development Milestones

Featured News & Press Releases

Oct 12, 2020: Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for retinoblastoma treatment

Jan 24, 2019: SJD Barcelona Children’s Hospital is, for the first time in the world, treating a childhood cancer of the retina with the oncolytic virus VCN-01

Feb 29, 2016: VCN Biosciences Provides Update on its lead candidate VCN-01

Dec 01, 2015: Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma

Nov 23, 2015: Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma

Aug 23, 2015: Cellceutix Requesting Meeting With FDA on Kevetrin for Pediatric Retinoblastoma

Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma

Oct 31, 2012: VCN Biosciences at the 2012 Annual Meeting of the European Society of Cell & Gene Therapy in Versailles

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Retinoblastoma, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Retinoblastoma – Pipeline by Aileron Therapeutics Inc, 2021

Retinoblastoma – Pipeline by APEIRON Biologics AG, 2021

Retinoblastoma – Pipeline by Ascentage Pharma Group International, 2021

Retinoblastoma – Pipeline by Canget BioTekpharma LLC, 2021

Retinoblastoma – Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2021

Retinoblastoma – Pipeline by Innovation Pharmaceuticals Inc, 2021

Retinoblastoma – Pipeline by Oxular Ltd, 2021

Retinoblastoma – Pipeline by PepVax Inc, 2021

Retinoblastoma – Pipeline by Seneca Therapeutics Inc, 2021

Retinoblastoma – Pipeline by Spectocular LLC, 2021

Retinoblastoma – Pipeline by Targeted Therapy Technologies LLC, 2021

Retinoblastoma – Pipeline by VCN Biosciences SL, 2021

Retinoblastoma – Pipeline by Y-mAbs Therapeutics Inc, 2021

Retinoblastoma – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Retinoblastoma, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports